Abstract
The present series of studies were designed to investigate the 5-HT2C receptor agonist Ro 60-0175 on cocaine- and food-maintained behavior in the rat. Ro 60-0175 (0.1–3 mg/kg, s.c.) reduced cocaine (15 mg/kg, i.p.)-induced hyperactivity. This inhibitory effect of Ro 60-0175 (1 mg/kg, s.c.) was completely blocked by pretreatment with the selective 5-HT2C antagonist SB 242,084 (0.5 mg/kg, i.p.). In further studies, Ro 60-0175 (1–3 mg/kg, s.c.) reduced responding for both food (45-mg Noyes pellet) and cocaine (0.25 mg/infusion) maintained under identical schedules of reinforcement (fixed ratio (5), time out 1 min, 60-min duration). The effect on food-maintained responding was blocked by SB 242,084 (0.5 mg/kg, i.p.). Ro 60-0175 (0.3–3 mg/kg, s.c.) also reduced the breakpoint for cocaine self-administration under a progressive ratio schedule of reinforcement. After a period of extinction training, where cocaine solution was substituted with saline, an acute priming injection of cocaine (15 mg/kg, i.p.) but not Ro 60-0175 (1 mg/kg, s.c.) reinstated cocaine responding. In this model of relapse, Ro 60-0175 (1–3 mg/kg, s.c.) pretreatment attenuated the priming effect of acute cocaine injection. In a final series of studies to examine the cataleptogenic properties of Ro 60-0175, very mild indices of catalepsy were observed at the 3 mg/kg dose only. These catalepsy scores were significantly lower than that produced by haloperidol (0.5 mg/kg, s.c.). In further tests of motor function using the Rotarod, deficits were again seen at the 3 mg/kg dose, but not at lower doses. Taken together, these studies suggest that, in addition to reducing food intake, 5-HT2C receptor agonists reduce cocaine-reinforced behavior. This would be consistent with electrophysiological and biochemical evidence suggesting an important modulatory influence of 5-HT2C receptor activation on mesolimbic dopamine function.
Footnotes
-
Send reprint requests to: G. A. Higgins, PRBN-B, Bau 72/150, F. Hoffmann-La Roche Ltd., Basel CH-4070, Switzerland. E-mail:guy_a.higgins{at}roche.com
-
↵1 Funding for this work was provided by F. Hoffman-La Roche AG.
-
↵2 Paul Fletcher is a Career Scientist of the Ontario Ministry of Health. The work conducted in his laboratory was supported by an operating grant from the Medical Research Council of Canada.
- Abbreviations:
- 5-HT
- 5-hydroxytryptamine (serotonin)
- Ro 60-0175
- (S)-2-(chloro-5-fluoro-indol-1-yl)-1-methylethylamine 1:1 C4H4O4
- SB 242,084
- 6-chloro-5-methyl-1-[2-(2-methylpyridyl-3-oxy)pyrid-5-yl carbomyl] indoline
- FR5TO1-min
- fixed ratio (5), time-out 1 min
- SSRI
- serotonin-selective reuptake inhibitor
- PR
- progressive ratio
- VTA
- ventral tegmental area
- DA
- dopamine
- WT
- wild type
- PVN
- paraventricular nucleus
- NA
- noradrenaline
- GABA
- γ-aminobutyric acid
- Received May 15, 2000.
- Accepted August 28, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|